Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Mitoxantrone-induced suicidal erythrocyte death.
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Glatiramer acetate during early pregnancy: A prospective cohort study.
Receptos initiates clinical trials for S1P1 agonist program, aimed at multiple sclerosis
[The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis.]
Daclizumab for relapsing remitting multiple sclerosis.
Efficacy and Tolerability of BAF312 in Patients With Polymyositis
Astaxanthin as a Potential Neuroprotective Agent for Neurological Diseases.
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model.
Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects.
Fingolimod is a potential novel therapy for multiple sclerosis.
The INCAT disability score: A critical analysis of its measurement properties.
Study to evaluate early glatiramer acetate treatment in delaying conversion to CDMS of subjects presenting with CIS (PreCISe)
Cortical demyelination and diffuse white matter injury in multiple sclerosis.
Genzyme submits applications to FDA and EMA for approval of LEMTRADA™ (alemtuzumab) for multiple sclerosis
Better Prognosis of Multiple Sclerosis in Patients Who Experienced a Full-Term Pregnancy.
New Tysabri data reaffirm substantial efficacy in treatment of people with MS and demonstrate stability of anti-JCV antibody status
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment.
Glatiramer acetate treatment negatively regulates type I interferon signaling.

Pages